{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:19:40Z","timestamp":1788347980755,"version":"build-2803163510"},"reference-count":48,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T00:00:00Z","timestamp":1618876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Despite current blood safety measures, transfusion recipients can experience transfusion\u2010related adverse reactions. Monitoring these reactions can aid in understanding the effectiveness of current transfusion safety measures. Data from the National Healthcare Safety Network Hemovigilance Module were used to quantify adverse reaction risk.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Facilities reporting at least one\u2009month of transfused blood components and transfusion\u2010related adverse reactions during January 2013\u2013December 2018 were included. Adverse reaction rates (number per 100,000 components transfused) were calculated for transfused components stratified by component type, collection, and modification methods.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>During 2013\u20132018, 201 facilities reported 18,308 transfusion\u2010related adverse reactions among 8.34 million blood components transfused (220\/100,000). Adverse reactions were higher among apheresis (486\/100,000) and pathogen\u2010reduced platelets (579\/100,000) than apheresis red blood cells (197\/100,000). Allergic reactions (41%) were most common. There were 23 fatalities and 9% of all adverse reactions were serious (severe, life\u2010threatening, or fatal). Reactions involving pulmonary complications (transfusion\u2010associated circulatory overload, transfusion\u2010related acute lung injury and transfusion\u2010associated dyspnea) accounted for 35% of serious reactions but 65% of fatalities. Most (76%) of the 37 transfusion\u2010transmitted infections were serious; none involved pathogen\u2010reduced components.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>One in 455 blood components transfused was associated with an adverse reaction although the risk of serious reactions (1 in 6224) or transfusion\u2010transmitted infections (1 in 225,440) was lower. Some serious reactions identified were preventable, suggesting additional safety measures may be beneficial. Higher reaction rates identified among pathogen\u2010reduced platelets require further study. These findings highlight the importance of monitoring reactions through national hemovigilance to inform current safety measures and the need for strategies to increase healthcare facility participation.<\/jats:p><\/jats:sec>","DOI":"10.1111\/trf.16362","type":"journal-article","created":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T22:42:53Z","timestamp":1619044973000},"page":"1424-1434","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Transfusion\u2010related adverse reactions: Data from the <scp>National Healthcare Safety Network Hemovigilance Module<\/scp> \u2014 <scp>United States<\/scp>, 2013\u20132018"],"prefix":"10.1111","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3233-9466","authenticated-orcid":false,"given":"Ian","family":"Kracalik","sequence":"first","affiliation":[{"name":"Division of Healthcare Quality Promotion Centers for Disease Control and Prevention  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9305-9228","authenticated-orcid":false,"given":"Sanjida","family":"Mowla","sequence":"additional","affiliation":[{"name":"Oak Ridge Institute for Science and Education (ORISE) Centers for Disease Control and Prevention  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridhar V.","family":"Basavaraju","sequence":"additional","affiliation":[{"name":"Division of Healthcare Quality Promotion Centers for Disease Control and Prevention  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6938-6683","authenticated-orcid":false,"given":"Mathew R.P.","family":"Sapiano","sequence":"additional","affiliation":[{"name":"Division of Healthcare Quality Promotion Centers for Disease Control and Prevention  Atlanta Georgia USA"},{"name":"Lantana Consulting Group, Inc.  East Thetford Vermont USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,4,20]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01313-6"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12918"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15654"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-833988"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13730"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13475"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13330"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15275"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12547"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2013.09.013"},{"key":"e_1_2_6_12_1","unstructured":"Food and Drug Adminsitration.Fatalities reported to FDA following blood collection and transfusion FY2013. [cited 2020 2 Feb]. Available from:http:\/\/wayback.archive-it.org\/7993\/20171115110739\/https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/SafetyAvailability\/ReportaProblem\/TransfusionDonationFatalities\/UCM393080.pdf.2013."},{"key":"e_1_2_6_13_1","unstructured":"Food and Drug Adminsitration.Fatalities reported to FDA following blood collection and transfusion FY2018. Available from:https:\/\/www.fda.gov\/media\/136907\/download.2018."},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2012.03595.x"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02317.x"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2006.00783.x"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2010.01366.x"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12980"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2019.01.001"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13872"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15008"},{"key":"e_1_2_6_22_1","unstructured":"Food and Drug Administration.Bacterial risk control strategies for blood collection establishments and transfusion services to enhance the safety and availability of platelets for transfusion. [cited 2020 June 15]. Available from:https:\/\/www.fda.gov\/media\/123448\/download.2019."},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1600897"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15043"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714977"},{"key":"e_1_2_6_26_1","unstructured":"National Healthcare Safety Network (NHSN) Biovigilance Component Hemovigilance Module Surveillance Protocol.2018. Available from:https:\/\/www.cdc.gov\/nhsn\/pdfs\/biovigilance\/bv-hv-protocol-current.pdf."},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15604"},{"key":"e_1_2_6_28_1","volume-title":"Proceedings from the national summit on overuse","author":"Joint Commission","year":"2012"},{"key":"e_1_2_6_29_1","first-page":"1545","article-title":"Factors influencing moderate to severe reactions to PLT transfusions: Experience of the TRAP multicenter clinical","volume":"43","author":"Enright H","year":"2003","journal-title":"Trial"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12622"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02128.x"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1309\/AJCP6SBPOX0UWHEK"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2002.00202.x"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12150"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14308"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14168"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-07-655944"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03247.x"},{"key":"e_1_2_6_39_1","first-page":"387","article-title":"Passive reporting greatly underestimates the rate of transfusion\u2010associated circulatory overload after platelet","volume":"108","author":"Raval J","year":"2015","journal-title":"Transfusion"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aeg101"},{"key":"e_1_2_6_41_1","unstructured":"Annual Serious Hazards of Transfusion (SHOT) Report. Available from:https:\/\/www.shotuk.org\/wp-content\/uploads\/myimages\/SHOT-Report-2018_Web_Version-1.pdf.2018."},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/tme.12142"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30081-X"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30080-8"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13023"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.0041-1132.2004.00609.x"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2003.08.013"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1159\/000489900"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2017.07.001"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.16362","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/trf.16362","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.16362","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T07:10:06Z","timestamp":1693552206000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.16362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,20]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.1111\/trf.16362"],"URL":"https:\/\/doi.org\/10.1111\/trf.16362","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,20]]},"assertion":[{"value":"2020-10-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}